RT Journal
A1 Franklin T, Wang Z, Suh JJ, et al
T1 EFfects of varenicline on smoking cue–triggered neural and craving responses
JF Archives of General Psychiatry
JO Archives of General Psychiatry
YR 2011
FD May 2
VO 68
IS 5
SP 516
OP 526
DO 10.1001/archgenpsychiatry.2010.190
UL http://dx.doi.org/10.1001/archgenpsychiatry.2010.190
AB 
Numerous factors are involved in the motivation to smoke and are associated with relapse, including stress, peer pressure, availability, menstrual cycle phase, and even weight management.1- 5 However, smoking cue–induced and withdrawal-induced cravings are 2 of the major contributors to relapse.6- 9 Inability to combat withdrawal-induced craving, which declines within a month,10 plays a role in early relapse. Nevertheless, smokers report that smoking cues (eg, seeing a pack of cigarettes, socializing with others who smoke, and even internal mood states repeatedly associated with smoking) can trigger relapse months or even years after quitting. Some smokers who are thought to possess high “cue reactivity” are especially vulnerable and have an increased probability of relapse initiated by exposure to smoking cues.11- 12 Therefore, treatments that target cue reactivity are important, particularly for cue-vulnerable individuals, but the effect of existing smoking cessation medications on smoking cue reactivity has not been thoroughly investigated. Thus far, research has focused on reduction of withdrawal and nicotine reward, which are known mechanisms underlying the effectiveness of first-line smoking cessation agents, such as varenicline, nicotine replacement therapy, and bupropion hydrochloride.13- 15